PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Wednesday, May 31, 2023: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the first quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q1 2023
2023 2022 2022
TSEK Jan-Mar Jan-Mar Jan-Dec
Profit/loss
Other income 5,315 1,317 5,183
Profit/loss before depreciation (EBITDA -5,029 -5,018 -34,129
Operating profit/loss before net financials -5,029 -5,018 -34,129
Net financials 2 3 81
Netprofit/loss for the period -5,027 -5,015 -34,048
Earnings per share (SEK) -0.18 -0.18 -1.09
Highlights during Q1 2023- March 29, Biosergen provides Phase 2 clinical development strategy update.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
Highlights after the period
There have been no highlighe'ts after the period
The Financial report can be found on our website: https://biosergen.net/investors/filings